WVP
YMAB

Worth Venture Partners’s Y-mAbs Therapeutics YMAB Stock Holding History

Worth Venture Partners’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-104,487
Closed -$523K – 201
2023
Q1 		$523K Buy
+104,487
New +$427K 0.26% 82

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Worth Venture Partners's YMAB Position: Q2 2023 in Review

Worth Venture Partners sold out of Y-mAbs Therapeutics (YMAB) in Q2 2023, closing a stake of 104,487 shares — an estimated $523K sold.

Worth Venture Partners first reported a position in YMAB in Q1 2023 and held it in 1 quarter. The position peaked at $523K in Q1 2023. 95 funds tracked by Wall St. Rank hold YMAB as of Q2 2023.

  • Worth Venture Partners reported no remaining Y-mAbs Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Worth Venture Partners sold 104,487 Y-mAbs Therapeutics shares in Q2 2023, an estimated $523K.
  • Worth Venture Partners first reported a position in Y-mAbs Therapeutics in Q1 2023 and held it in 1 quarter.
  • Worth Venture Partners's Y-mAbs Therapeutics position peaked at $523K in Q1 2023.
  • 95 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2023.

Based on Worth Venture Partners's 13F filing for Q2 2023, filed 14 Aug 2023.